Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Trans Genic Files Patent Application for Antibody against Novel Lung Cancer Marker
September 26, 2011
- US FDA Completes Review of Protocol for PIII Trial of Collategene: AnGes MG
September 26, 2011
- Astellas: OAB Treatment Betanis Tablets
September 26, 2011
- Ono/Astellas: Once-Every-Four-Weeks Formulation of Recalbon, Bonoteo
September 26, 2011
- Takeda Aiming to Make Comeback in Diabetes Market
September 25, 2011
- Novartis Grows 7% Driven by New Products: President Mitani
September 22, 2011
- PIII Trial for Brain Function Imaging Agent Starts: Nihon Medi-Physics
September 21, 2011
- Nichi-Iko to Postpone M&A of Nichi-iko Pharma Factory Until June 2012
September 21, 2011
- Kaken President Onuma Targets ¥20 Billion in Operating Profits in 2015
September 21, 2011
- Kowa Yakuhin Sets Up Private Electric Generators as Part of Disaster Measures
September 20, 2011
- Sitagliptin Receives Approval for Use in Combination with Insulin: MSD, Ono
September 20, 2011
- CellCept Obtains Approval for Additional Pediatric Dosage: Chugai
September 20, 2011
- Janssen Obtains Additional Indication for Treatment-Naïve MM
September 20, 2011
- Takeda Initiates Domestic PIII Trials for Successor to Takepron
September 20, 2011
- NanoCarrier Obtains Substance Patent for Its “pH-Responsive Micelle” in China
September 19, 2011
- Sales of Ethical Drugs Up 0.1% in July: Crecon & Research Consulting
September 19, 2011
- Sandoz to Use Its Unique Anticancer Drug Container for More Anticancer Drugs
September 19, 2011
- Nichi-Iko, Pfizer Apply for Add’l Indication for Generic Cisplatin Using Data from Public Domain
September 19, 2011
- M3 to Start “Web Lecture” Service for Drug Makers
September 19, 2011
- All-case PMS Completed for Colorectal Cancer Treatment Erbitux: Merck Serono
September 19, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…